Should female sex workers be offered HPV vaccination

作者: Maarten F. Schim van der Loeff , Alex Vorsters , Elske Marra , Pierre Van Damme , Arjan Hogewoning

DOI: 10.1080/21645515.2019.1602432

关键词:

摘要: Prophylactic vaccines are efficacious in preventing Human Papillomavirus (HPV) infection and subsequent cervical intraepithelial neoplasia (CIN), cancer, other anogenital cancers, warts. Female sex workers (SW) at increased risk of acquiring sexually transmitted infections, including HPV. There several reasons to offer HPV vaccination SW: they high for often unvaccinated, the immunogenicity vaccine is also excellent previously exposed women. Furthermore, women with disease caused by may still benefit from vaccination. The efficacy vaccinating mid-adult (26-44 years old) against persistent CIN2+ good. Although an SW have been infected or HPV, she not all vaccine-included hrHPV types. Vaccination induces mucosal immunity via production neutralizing antibodies on surface female genital tract, thus potential transmission clients. Nevertheless, some considerations argue offering SWs. Current only prophylactic as such, do affect current infections. Women who cleared so again need Fewer might be naive HPV-types than currently thought. has probably no effect latent Vaccinating sometime after sexual debut could too late, infections already occurred. Taken together, data suggest that health benefits, community, but sufficient evidence lacking. In certain cases, recommended. Evidence-based, public decisions concerning challenging facilitated more research this high-risk group.

参考文章(44)
John T. Schiller, Philip Davies, Delivering on the promise: HPV vaccines and cervical cancer. Nature Reviews Microbiology. ,vol. 2, pp. 343- 347 ,(2004) , 10.1038/NRMICRO867
Marc Arbyn, Lan Xu, Cindy Simoens, Pierre PL Martin-Hirsch, Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors Cochrane Database of Systematic Reviews. ,vol. 5, pp. 0- 0 ,(2013) , 10.1002/14651858.CD009069.PUB3
Patti E. Gravitt, The known unknowns of HPV natural history Journal of Clinical Investigation. ,vol. 121, pp. 4593- 4599 ,(2011) , 10.1172/JCI57149
X Castellsagué, N Muñoz, P Pitisuttithum, D Ferris, J Monsonego, K Ault, J Luna, E Myers, S Mallary, O M Bautista, J Bryan, S Vuocolo, R M Haupt, A Saah, End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age British Journal of Cancer. ,vol. 105, pp. 28- 37 ,(2011) , 10.1038/BJC.2011.185
Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Celine Bouchard, Constance Mao, Jesper Mehlsen, Edson D Moreira Jr, Yuen Ngan, Lone Kjeld Petersen, Eduardo Lazcano-Ponce, Punnee Pitisuttithum, Jaime Alberto Restrepo, Gavin Stuart, Linn Woelber, Yuh Cheng Yang, Jack Cuzick, Suzanne M Garland, Warner Huh, Susanne K Kjaer, Oliver M Bautista, Ivan SF Chan, Joshua Chen, Richard Gesser, Erin Moeller, Michael Ritter, Scott Vuocolo, Alain Luxembourg, None, A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women The New England Journal of Medicine. ,vol. 372, pp. 711- 723 ,(2015) , 10.1056/NEJMOA1405044
KM Leung, Gary PS Yeoh, HN Cheung, Francois Y Fong, KW Chan, Prevalence of abnormal Papanicolaou smears in female sex workers in Hong Kong. Hong Kong Medical Journal. ,vol. 19, pp. 203- ,(2013) , 10.12809/HKMJ133917
LISA E. MANHART, LAURA A. KOUTSKY, Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually Transmitted Diseases. ,vol. 29, pp. 725- 735 ,(2002) , 10.1097/00007435-200211000-00018
A. Szarewski, W.A.J. Poppe, S.R. Skinner, C.M. Wheeler, J. Paavonen, P. Naud, J. Salmeron, S.-N. Chow, D. Apter, H. Kitchener, X. Castellsagué, J.C. Teixeira, J. Hedrick, U. Jaisamrarn, G. Limson, S. Garland, B. Romanowski, F.Y. Aoki, T.F. Schwarz, F.X. Bosch, D.M. Harper, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, M. Lehtinen, G. Dubin, , Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. web science. ,vol. 131, pp. 106- 116 ,(2012) , 10.1002/IJC.26362
E. A. Joura, S. M. Garland, J. Paavonen, D. G. Ferris, G. Perez, K. A. Ault, W. K. Huh, H. L. Sings, M. K. James, R. M. Haupt, , Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data BMJ. ,vol. 344, ,(2012) , 10.1136/BMJ.E1401